Therapeutic | Etesevimab |
Target | SARS-CoV-2 Spike RBD |
Heavy Chain | EVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTFYADSVKGRFTISRDNSMNTLFLQMNSLRAEDTAVYYCARVLPMYGDYLDYWGQGTLVTVSS |
Light Chain | DIVMTQSPSSLSASVGDRVTITCRASQSISRYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPPEYTFGQGTKLEIK |
100% seqID Fv Structure | 7c01%3ACD%3AHL [Fvs: ] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 7c01%3ACD%3AHL [Fvs: ] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (August '23) | Approved |
Estimated Status (August '23) | NFD |
Recorded Developmental Technology | na |
INN Year Proposed | 2020 |
INN Year Recommended | None |
Companies Involved | Eli Lilly and Company%3BInstitute of Microbiology of the Chinese Academy of Sciences%3BShanghai Junshi Biosciences |
Conditions Approved | COVID-19 |
Conditions Active | na |
Conditions Discontinued | na |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]